The results of this study suggest that 6-month treatment with doxycycline in patients with metastatic prostate cancer, with or without castration resistance, not only enhances the reduction in prostate-specific antigen (PSA) levels but also has a significant impact on patients’ quality of life and, potentially, cognitive function. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.